DMKJ
MRNS

David M. Knott Jr’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

David M. Knott Jr’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46,697
Closed -$555K – 155
2021
Q4 		$555K Buy
+46,697
New +$539K 0.19% 66

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

David M. Knott Jr's MRNS Position: Q1 2022 in Review

David M. Knott Jr sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2022, closing a stake of 46,697 shares — an estimated $555K sold.

David M. Knott Jr first reported a position in MRNS in Q4 2021 and held it in 1 quarter. The position peaked at $555K in Q4 2021. 83 funds tracked by Wall St. Rank hold MRNS as of Q1 2022.

  • David M. Knott Jr reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • David M. Knott Jr sold 46,697 Marinus Pharmaceuticals, Inc shares in Q1 2022, an estimated $555K.
  • David M. Knott Jr first reported a position in Marinus Pharmaceuticals, Inc in Q4 2021 and held it in 1 quarter.
  • David M. Knott Jr's Marinus Pharmaceuticals, Inc position peaked at $555K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2022.

Based on David M. Knott Jr's 13F filing for Q1 2022, filed 16 May 2022.